EUCTR2012-000600-15-SE进行中（未招募）1 期
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 580
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets protocol-defined criteria
- •Active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic Leukemia 2008 criteria for requiring treatment
- •Measurable nodal disease by computed tomography
- •Relapsed or refractory CLL or SLL following at least 1 prior line of systemic therapy consisting of at least 2 cycles of a chemotherapy containing regimen
- •Eastern Cooperative Oncology Group Performance Status score of 0 or 1
- •Hematology and biochemical values within protocol defined limits
- •Agrees to protocol-defined use of effective contraception
- •Women of childbearing potential must have negative blood or urine pregnancy test at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 174
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 406
排除标准
- •Recent therapeutic interventions within 3
- •(chemotherapy/radiotherapy) to 10 weeks (immunotherapy)
- •Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior randomization in any other clinical study evaluating ibrutinib
- •The presence of deletion of the short arm of chromosome 17
- •Patients previously treated with a bendamustine-containing regimen who did not achieve a response or who relapsed and required treatment within 24 months of treatment with that regimen
- •Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
- •Received a hematopoietic stem cell transplant
- •Known central nervous system leukemia/lymphoma or Richter's transformation
- •Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
- •Chronic use of corticosteroids
- •History of prior malignancy, except: malignancy treated with curative intent and with no known active disease present for >=3 years before randomization; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease
- •History of stroke or intracranial hemorrhage within 6 months prior to randomization; or clinically significant cardiovascular disease
- •Requires anticoagulation with warfarin or equivalent vitamin K antagonists or treatment with strong CYP3A4/5 inhibitors
- •Known history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or C
- •Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
- •A woman who is pregnant or breast feeding, or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
研究者
相似试验
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864EUCTR2012-000600-15-PTJanssen-Cilag International NV580
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.EUCTR2012-000600-15-GBJanssen-Cilag International NV578
进行中（未招募）
1 期
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASHigh- or very-high risk, localized or locally advanced prostate cancerCTIS2023-505246-26-00Janssen - Cilag International1,315
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 14.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000600-15-GRJanssen-Cilag International NV578
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 14.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000600-15-ESJanssen-Cilag International NV580